“We’re In The ‘Ozempic Era

Ozempic, a brand name for the medication Semaglutide , was originally designed to help patients with type 2 diabetes improve their glycemic control. But in March 2024, the US Food and Drug Administration made a controversial, and profitable, decision by expanding the indication of the peptide to help obese people lose weight and reduce the risk of cardiovascular incidents.